|Articles|April 25, 2004

Choice of ED Rx now a matter of patient preference

But open discussions of sexual dysfunction have led to 'hucksterism'and false claims

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Oral testosterone undecanoate shows promising results for first use in the real world

ByUrology Times staff

November 3rd 2021

Pivotal data for lumasiran in PH1 published in NEJM

ByJason M. Broderick

April 1st 2021

Nedosiran explored in primary hyperoxaluria type 3

ByJason M. Broderick

February 26th 2021

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

ByJason M. Broderick

February 9th 2021

FDA approves androgen inhibitor for metastatic PCa

September 12th 2012

Latest CME

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Choice of ED Rx now a matter of patient preference

Related Content

Oral testosterone undecanoate shows promising results for first use in the real world

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

FDA approves androgen inhibitor for metastatic PCa

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer

Individualizing androgen pathway therapy in mCSPC

BOND-003 Cohort C: Efficacy Results

BOND-003 Cohort C: Study Design and Patient Population